Canada

ABK Biomedical raises $35M USD to commercialize breakthrough Liver Cancer Treatment
Medical device innovator ABK Biomedical has raised $35 million USD ($49.1 million CAD) in Series D funding to bring its Eye90™ microspheres, a next-generation treatment for liver cancer, to market.

The best Articles in our Network